Name (Synonyms) | Correlation | |
---|---|---|
drug1332 | Hydroxychloroquine/Chloroquine Wiki | 0.50 |
drug151 | Adalimumab Wiki | 0.50 |
drug2166 | Placebo to match filgotinib Wiki | 0.50 |
drug1106 | Filgotinib Wiki | 0.50 |
drug562 | COVID-19 infection Wiki | 0.50 |
drug2165 | Placebo to match adalimumab Wiki | 0.50 |
drug2314 | Questionnaire by phone call Wiki | 0.50 |
drug534 | COVID-19 Breastfeeding Support Wiki | 0.50 |
drug535 | COVID-19 Convalescent Plasma Wiki | 0.45 |
drug531 | COVID-19 Wiki | 0.35 |
Name (Synonyms) | Correlation | |
---|---|---|
D001168 | Arthritis NIH | 0.55 |
D008180 | Lupus Erythematosus, Systemic NIH | 0.41 |
D001167 | Arteritis NIH | 0.35 |
D012859 | Sjogren's Syndrome NIH | 0.35 |
D011111 | Polymyalgia Rheumatica NIH | 0.29 |
D013700 | Giant Cell Arteritis NIH | 0.29 |
D003095 | Collagen Diseases NIH | 0.25 |
D001327 | Autoimmune Diseases NIH | 0.25 |
D012216 | Rheumatic Diseases NIH | 0.20 |
D001172 | Arthritis, Rheumatoid NIH | 0.18 |
D003141 | Communicable Diseases NIH | 0.04 |
D007239 | Infection NIH | 0.03 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001369 | Arthritis HPO | 0.55 |
HP:0002725 | Systemic lupus erythematosus HPO | 0.41 |
HP:0012089 | Arteritis HPO | 0.35 |
HP:0002960 | Autoimmunity HPO | 0.25 |
HP:0001370 | Rheumatoid arthritis HPO | 0.18 |
There are 4 clinical trials
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who are naive to biologic disease-modifying anti-rheumatic drug (DMARD) therapy. The study consists of two parts, the Main Study and the Long Term Extension (LTE).
Description: ACR20 is calculated as an at least 20% improvement from baseline in both tender and swollen joint counts and an at least 20% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, health assessment questionnaire - disability index (HAQ-DI) and an acute-phase reactant high sensitivity C-reactive protein (hsCRP).
Measure: Percentage of Participants who Achieve an American College of Rheumatology (ACR) 20% Improvement Response at Week 12 Time: Week 12Description: PASDAS is a composite disease activity measure for psoriatic arthritis. The PASDAS covers the physician's global assessment of disease activity and participant's global assessment of disease activity, the Short-Form Health Survey (SF-36) Physical Component Score (PCS), swollen and tender joint counts, enthesitis and dactylitis, as well as hsCRP. A lower score indicates better function.
Measure: Change from Baseline in Psoriatic Arthritis Disease Activity Score (PASDAS) Time: Baseline; Weeks 4, 16Description: Minimal disease activity will be determined by tender and swollen joint counts, PASI or body surface area (BSA), participant's assessment of pain, participant's global assessment of disease activity, HAQ-DI, and SPARCC Enthesitis Index.
Measure: Percentage of Participants who Achieved Minimal Disease Activity (MDA) Response Time: Weeks 4, 8, 12, 16Description: VLDA will be determined by tender and swollen joint counts, PASI or BSA, participant's assessment of pain, participant's global assessment of disease activity, HAQ-DI, and SPARCC Enthesitis Index.
Measure: Percentage of Participants who Achieved Very Low Disease Activity (VLDA) Response Time: Weeks 4, 8, 12, 16Description: DAPSA is a psoriatic arthritis disease activity measure, calculated by summing swollen and tender joint counts, participant's assessment of pain, participant's global assessment of disease activity, and hsCRP.
Measure: Change from Baseline in Disease Activity in Psoriatic Arthritis (DAPSA) Time: Baseline; Weeks 2, 4, 8, 12, 16Description: The physician's global assessment of psoriasis is used to determine the participant's psoriasis lesions overall at a given time point. The participant's psoriasis disease activity will be assessed by a physician, using a 6-point scale, which ranges from 0 (cleared) to 5 (severe).
Measure: Change from Baseline in Physician's Global Assessment of Psoriasis (PhGAP) in Participants with Psoriasis Covering ≥ 3% of the BSA at Baseline Time: Baseline; Weeks 2, 4, 8, 12, 16Description: Each fingernail was assessed for psoriasis with mNAPSI, and the scores of all 10 fingernails were combined. Investigators assessed each nail abnormality for each of a participant's nails by grading 3 features or groups of features (pitting, onycholysis and oil-drop dyschromia, and crumbling) and noting the presence or absence of 4 features (leukonychia, splinter hemorrhages, hyperkeratosis, and red spots in the lunula). The range of possible scores was 0 to 130, with a score of 0 indicating absence of nail psoriasis and a score of 130 indicating the most severe nail psoriasis. A decrease in mNAPSI score indicates improvement.
Measure: Change from Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) in Participants with Psoriatic Nail Involvement at Baseline Time: Baseline; Weeks 4, 8, 12, 16Description: Enthesitis will be assessed using LEI. The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).
Measure: Change from Baseline in Leeds Enthesitis Index (LEI) in Participants with Enthesitis at Baseline Time: Baseline; Weeks 4, 8, 12, 16Description: The PsAID questionnaire assesses the impact of PsA on people's lives. It is a 12-item questionnaire, where each item will be scored between 0 and 10. All items are prioritized according to importance of the health domain it represents. A higher score on the PsAID indicates more impact of the disease.
Measure: Change from Baseline in 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) Time: Baseline; Weeks 4, 16Description: PASDAS LDA is defined as PASDAS ≤ 3.2.
Measure: Percentage of Participants with Psoriatic Arthritis Disease Activity Score (PASDAS) Low Disease Activity (LDA) Time: Baseline; Weeks 4, 16Description: PASDAS remission is defined as PASDAS ≤ 1.9.
Measure: Percentage of Participants who Achieve PASDAS Remission Time: Baseline; Weeks 4, 16Description: ACR20 is calculated as an at least 20% improvement from baseline in both tender and swollen joint counts and an at least 20% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, HAQ-DI and an acute-phase reactant hsCRP.
Measure: Percentage of Participants who Achieve an American College of Rheumatology 20% Improvement Response Time: Baseline; Weeks 2, 4, 8, 16Description: ACR50 is calculated as an at least 50% improvement from baseline in both tender and swollen joint counts and an at least 50% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, HAQ-DI, and an acute-phase reactant hsCRP.
Measure: Percentage of Participants who Achieve an American College of Rheumatology 50% Improvement Response Time: Weeks 2, 4, 8, 12, 16Description: ACR70 is calculated as an at least 70% improvement from baseline in both tender and swollen joint counts and an at least 70% improvement in at least 3 of the following 5 measures: participant's global assessment of disease activity, physician's global assessment of disease activity, participant'ss assessment of pain, HAQ-DI and an acute-phase reactant (high sensitivity C-reactive protein [hsCRP]).
Measure: Percentage of Participants who Achieve an American College of Rheumatology 70% Improvement Response Time: Baseline; Weeks 2, 4, 8, 12, 16Description: Components of ACR include tender and swollen joint counts, participant's global assessment of disease activity, physician's global assessment of disease activity, participant's assessment of pain, HAQ-DI and hsCRP.
Measure: Change from Baseline in Individual Components of the American College of Rheumatology Response Criteria Time: Baseline; Weeks 2, 4, 8, 12, 16Description: DAS28(CRP) is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), participant's global assessment of disease activity and hsCRP. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.
Measure: Change from Baseline in Participants who Achieve Disease Activity Score 28 (DAS28) C-Reactive Protein (CRP) Time: Baseline; Weeks 2, 4, 8, 12, 16Description: DAS28(CRP) LDA is defined as DAS28(CRP) ≤ 3.2.
Measure: Percentage of Participants who Achieve DAS28(CRP) LDA Time: Baseline; Weeks 2, 4, 8, 12, 16Description: DAS28(CRP) remission is defined as DAS28(CRP) < 2.6.
Measure: Percentage of Participants who Achieve DAS28(CRP) Remission Time: Baseline; Weeks 2, 4, 8, 12, 16Description: Time to achieve DAS28(CRP) LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAS28(CRP) LDA, or censored if a participant does not achieve DAS28(CRP) LDA or missing.
Measure: Time to Achieve DAS28(CRP) LDA Time: First dose date up to 16 weeksDescription: DAPSA LDA is defined as DAPSA ≤ 14.
Measure: Percentage of Participants who Achieve DAPSA LDA Time: Baseline; Weeks 2, 4, 8, 12, 16Description: DAPSA remission is defined as DAPSA ≤ 4.
Measure: Percentage of Participants who Achieve DAPSA Remission Time: Baseline; Weeks 2, 4, 8, 12, 16Description: Time to achieve DAPSA LDA is the number of days from the first dose date of study drug administration to the first time when a participant achieves DAPSA LDA, or censored if a participant does not achieve DAPSA LDA or missing.
Measure: Time to Achieve DAPSA LDA Time: First dose date up to 16 weeksDescription: PsARC consists of four components: assessment of joint tenderness and swelling utilizing 68/66 joint counts respectively, participant's global assessment of disease activity, and physician's global assessment of disease activity.
Measure: Percentage of Participants who Achieve Psoriatic Arthritis Response Criteria (PsARC) Response Time: Baseline; Weeks 2, 4, 8, 12, 16Description: PASI will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percent [%] to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.
Measure: Change from Baseline in Psoriasis Area and Severity Index (PASI) in Participants with Psoriasis Covering ≥ 3% of the BSA at Baseline Time: Baseline; Weeks 4, 8, 12, 16Description: The PASI50 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI50 response represents at least a 50% improvement from baseline in the PASI score.
Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 50% Improvement (PASI50) Response Time: Weeks 4, 8, 12, 16Description: The PASI75 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI75 response represents at least a 75% improvement from baseline in the PASI score.
Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 75% Improvement (PASI75) Response with Psoriasis Covering ≥ 3% of the Body Surface Area Time: Weeks 4, 8, 12, 16Description: The PASI90 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI90 response represents at least a 90% improvement from baseline in the PASI score.
Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 90% Improvement (PASI90) Response Time: Weeks 4, 8, 12, 16Description: The PASI100 will be assessed in participants with psoriasis covering ≥ 3% of the BSA at Baseline. A PASI100 response represents a 100% improvement from baseline in the PASI score.
Measure: Percentage of Participants who Achieve Psoriasis Area and Severity Index 100% Improvement (PASI100) Response Time: Weeks 4, 8, 12, 16Description: The SPARCC Enthesitis Index identifies the presence or absence of tenderness at 16 enthesial sites, including the bilateral Achilles tendons, plantar fascia insertion at the calcaneus, patellar tendon insertion at the base of the patella, quadriceps insertion into the superior border of the patella, supraspinatus insertion into the greater tuberosity of the humerus, and medial and lateral epicondyles. Tenderness is quantified as present (1) or absent (0) for each of the 16 sites, with an overall total score ranging from 0 to 16. Higher score indicates a greater number of sites that are affected by enthesitis.
Measure: Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants with Enthesitis at Baseline Time: Baseline; Weeks 4, 8, 12, 16Description: LDI quantitatively measures dactylitis using the circumference of involved digits and control digits and tenderness of involved digits. Digits affected by dactylitis are defined as those with an at least 10% difference in the ratio of circumference of the affected digit to the contralateral digit. The control digit is either the contralateral digit (digit on opposite hand or foot), or if the contralateral digit is also affected, values from a standard reference table. Tenderness of affected digits is assessed on a scale from 0 [no tenderness] to 3 [tender and withdrawn]. A higher LDI indicates worse dactylitis.
Measure: Change from Baseline in Leeds Dactylitis Index (LDI) in Participants with Dactylitis at Baseline Time: Baseline; Weeks 4, 8, 12, 16Description: TDC will be assessed in participants with dactylitis at Baseline. TDC is a simple count based on the presence or absence of tender joints.
Measure: Change from Baseline in Tender Dactylitis Count (TDC) Time: Baseline; Weeks 4, 8, 12, 16Description: HAQ-DI is used to monitor the participant's self-assessed physical function or disability. This 20 -question instrument assesses the degree of difficulty a person has in accomplishing tasks in 8 function areas (getting dressed, arising, eating, walking, hygiene, reaching, gripping, and activities). HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater dysfunction.
Measure: Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Time: Baseline; Weeks 2, 4, 8, 12, 16Description: FACIT-Fatigue is a 13-item questionnaire, with each item scored on a 5-point scale ranging from 0 (not at all) to 4 (very much). FACIT-Fatigue total score ranges 0 to 52. Higher scores represent better fatigue status.
Measure: Change from Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue) Time: Baseline; Weeks 4, 16Description: Composite endpoint of change from baseline in MCS and PCS scores in SF-36 Version 2. The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (MCS and PCS). MCS consists of social functioning, vitality, mental health, and role-emotional scales. PCS consists of physical functioning, bodily pain, role-physical, and general health scales. Each domain will be scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.
Measure: Change From Baseline in Mental Component Score (MCS) and Physical Component Score (PCS) of the Medical Outcomes SF-36 Version 2 Time: Baseline; Weeks 4, 16The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.
Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease
Measure: Disease activity Time: Last registration of disease activity in the medical journal before admission/inclusionDescription: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.
Measure: Immune modulating treatments Time: Current immune modulating treatments at admission/inclusionDescription: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups
Measure: Biomarkers Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.
Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.
Measure: Adjusted Odds Ratio Time: 4 months after inclusionThis study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking anti-malarial medications compared to those who do not. This registry includes approximately 2500 northern Alberta patients with inflammatory arthritis who receive highly complex therapies which may be associated with side effects. This program of data collection and research has been evaluating the effectiveness and safety as well as associated health care costs of rheumatoid and psoriatic arthritis patients since 2004. The principle investigators are based at the University of Alberta while the co-investigators are academic rheumatologists at the University of Alberta. The registry has approximately 900 patients taking anti-malarials combined with their complex therapies and ~ 1500 not on anti-malarials in combination with their complex therapies. We aim to perform a case control study evaluating the impact of anti-malarial drugs (eg. hydroxychloroquine and chloroquine) on the development of COVID-19 compared to those patients who are not on anti-malarial drugs over the next 6-12 months. In addition to frequent e-mail surveys screening for the clinical symptoms of COVID-19 and understanding their concomitant arthritis medication use, we will compare the healthcare outcomes of both groups of arthritis patients with and without COVID-19 for the duration of the pandemic. This information will provide critical information beyond an anecdotal level on whether or not anti-malarials truly provide a protective benefit against COVID-19 or reduce the severity of infection. A blood sample from all participants (Covid-19 positive and negative) will be drawn approximately six months into the study for measurement of antibodies to Covid-19 and possible blood types and HLA alleles. Additionally, this study will be linked to another study "Persistence of SARS-Cov2 in immunocompromised patients" which will specifically evaluate COVID-19 serology and nasopharyngeal swab findings in the subset of patients who develop COVID-19.
Description: Number of patients developing signs and symptoms of Covid-19 or other infections
Measure: Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group Time: 12 monthsDescription: Number of patients developing Covid-19 infection
Measure: Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group Time: 12 monthsDescription: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action
Measure: Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action Time: 12 monthsDescription: Quantitative measurement of Covid-19 serology to understand possible differences in degree of immune response adjusted for anti-malarial and/or biologic exposure
Measure: Quantification of Covid-19 antibodies in anti-malarial vs non-anti-malarial groups of inflammatory arthritis patients Time: 6 months